Neuraxis, INC
Neuraxis, Inc. (NYSE: NRXS) is a medical technology company developing neuromodulation therapies for gastrointestinal disorders of gut-brain interaction in children and adults. Its primary product, IB-Stim, is a non-implanted percutaneous electrical nerve field stimulation device cleared for patients aged eight and… From the company’s description.
Over the twelve months to Jun 30, 2026, Neuraxis, INC reported revenue of $5.32M, up 65.2% from a year earlier, and a net loss of $7.68M. Its operating margin was −144.5%, and operations used $5.62M in cash. In fiscal 2025, it reported revenue of $3.57M, up 32.9% from fiscal 2024, and a net loss of $7.80M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Neuraxis, INC does
In the company’s own words
Neuraxis, Inc. (NYSE: NRXS) is a medical technology company developing neuromodulation therapies for gastrointestinal disorders of gut-brain interaction in children and adults. Its primary product, IB-Stim, is a non-implanted percutaneous electrical nerve field stimulation device cleared for patients aged eight and older with functional abdominal pain associated with irritable bowel syndrome, functional dyspepsia and related nausea. The device stimulates nerves in the ear and is used alongside other therapies. Neuraxis also sells RED, an office-based device for evaluating rectal expulsion and rectal hypersensitivity in adults. Its customers include children’s hospitals, gastroenterology practices and, as its outreach expands, adult gastroenterologists and pain physicians. The company markets through a direct sales team, online channels and clinician outreach. It is conducting clinical trials of its stimulation technology for conditions including post-concussion syndrome, cyclic vomiting, post-operative pain and adult fibromyalgia. Neuraxis was established in 2011, initially as Innovative Health Solutions, and completed its initial public offering in 2023.
Company details
- Sector
- Health Care
- Industry (SIC)
- Electromedical Apparatus
- Headquarters
- CARMEL, IN
- Fiscal year end
- December
- CIK
- 1933567
- SIC
- 3845
Financial performance, year by year
Fiscal 2023–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Neuraxis, INC — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Neuraxis, INC’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Neuraxis, INC and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Neuraxis, INC's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Neuraxis, INC's last four quarterly filings that the numbers alone won't show?”